Ciba

In: Business and Management

Submitted By promanik1
Words 2192
Pages 9
An Open Letter from Kenneth Rogoff, International Monetary Fund, to Joseph Stiglitz, Author of Globalization and Its Discontents
2 July 2002 At the outset, I would like to stress that it has been a pleasure working closely with my World Bank colleagues—particularly my counterpart, Chief Economist Nick Stern—during my first year at the IMF. We regularly cross 19th Street to exchange ideas on research, policy, and life. The relations between our two institutions are excellent—this is not at issue. Of course, to that effect, I think it is also important, before I begin, for me to quash rumors about the demolition of the former PEPCO building that stood right next to the IMF until a few days ago. No, it's absolutely not true that this was caused by a loose cannon planted within the World Bank. Dear Joe: Like you, I came to my position in Washington from the cloisters of a tenured position at a topranking American University. Like you, I came because I care. Unlike you, I am humbled by the World Bank and IMF staff I meet each day. I meet people who are deeply committed to bringing growth to the developing world and to alleviating poverty. I meet superb professionals who regularly work 80-hour weeks, who endure long separations from their families. Fund staff have been shot at in Bosnia, slaved for weeks without heat in the brutal Tajikistan winter, and have contracted deadly tropical diseases in Africa. These people are bright, energetic, and imaginative. Their dedication humbles me, but in your speeches, in your book, you feel free to carelessly slander them. Joe, you may not remember this, but in the late 1980s, I once enjoyed the privilege of being in the office next to yours for a semester. We young economists all looked up to you in awe. One of my favorite stories from that era is a lunch with you and our former colleague, Carl Shapiro, at which the two of you…...

Similar Documents

Ciba Case

...Ciba-Geigy and the Newport Investment Proposal Portfolio planning at Ciba-Geigy From its founding in the mid-eighteenth century through the 1970s, Ciba-Geigy, Switzerland’s top chemical and pharmaceutical company, had evolved to include chemicals, dyes, pharmaceuticals, crop protection and animal health businesses. From the 1980s Ciba-Geigy used corporate portfolio planning to steer the corporate portfolio. The goal of corporate portfolio planning was to improve the process of resource allocation and performance assessment. The main idea was to differentiate the businesses – to give them different objectives, different types of managers, and to allow them to adopt the organization structure that was appropriate for each business. Before that, Ciba-Geigy had relied primarily on case-by-case discussions rather than formal guidelines to determine resource allocation in the corporation. Portfolio planning became part of the formal strategic planning system in 1984, with the introduction of annual strategy meetings with individual divisions. In August of each year, every unit was required to come before Ciba’s executive committee (CEC) to review its strategic plan, whose goals and performance objectives were determined by its role in the portfolio. For example, ‘growth’ divisions would have other objectives than ‘core’ divisions. The CEC sought confirmation that assumptions, objectives, and strategies were still valid and resource requirements still the same. Once the CEC had......

Words: 2123 - Pages: 9

Production Performance of the Existing Equipment

...msm clckwckmfc wc wc s sklcmwdofnmwmcskcsxlc,womcwmcslx sxxkcmldddddddddddddkjdmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmCovers the history of portfolio planning at CIBA-GEIGY, a leading Swiss chemical and pharmaceutical company, beginning with the introduction of the process in the mid-1980s. The discussion extends to the application of portfolio planning techniques to a specific investment proposal: the comprehensive modernization of a plant dedicated to the production of high-quality specialty pigmeEXAMPLE: The development of SMEs in the Eastern European countries during the first years of the transition period was difficult and they had to take of work as long as it brought money into a company. The subsequent rapid growth also offered multiple opportunities and the companies made full use of them. Thus, over 70% of Bulgarian companies, for example, had a portfolio that wasn´t related to a defined business strategy and vision for long term development, and its structure reflected the market situation. However, to stay competitive, small companies in all EU countries have had to re-think and optimize their activities; they have to search for new opportunities for their development. That is why they are being forced to create or update their strategy for the future development of the business, based on the prevailing conditions. The assessment of the products and services, offered by the......

Words: 552 - Pages: 3

Corning Incorporated: a Network Alliance

...market leader in their four sectors of business. There are some great proposals that have been presented to the management committee. The management team needs to decide if Corning wants to strive to be the front runner in just one business market or continue to grow each of the business sectors more conservatively. Corning’s joint venture with Ciba-Geigy is a good example of capability complementation. Both companies have complementary products and they both benefit from their strategic alliance in the medical diagnostics industry. While there is concern about the $40 million that is budgeted for R&D, this doesn’t necessarily take Ciba Corning off the market as a competitor in this product area. Ciba-Geigy, like Corning, has a vested interest in making this alliance profitable. Ciba-Geigy is willing to invest its own money back into Ciba Corning to assure that this happens. Neither of these companies poses a threat to the other, but both can transfer knowledge and work together to continue building their company within this segment of the laboratory sciences sector. The key thing about Corning’s relationship with Ciba-Geigy is that they share the same business fundamentals when it comes to their values and total quality management plan. When we take at look at Corning’s current position in the other three segments of this sector, clinical laboratory testing, pharmaceutical testing and environmental testing, we see that they are profitable in these areas. These......

Words: 1280 - Pages: 6

Forecasting Sunglasses

...Sunglasses After the onset of 1990s with the opening up of the Indian markets to foreign companies, one of the several products which gained prominence was  sunglasses. The credit for enlivening the Indian market must  go to the global player, Bausch & Lomb (B&L), the producer of the global brand, Ray Ban. There did exist an Indian market, fairly large. But this was limited basically to low-end or medium range products. Small quantities of high-end glasses were imported. In the recent years several others like Safilo of Italy, Ciba Vision, Johnson & Johnson have entered the market. The total market, estimated at  around 4.0 mn pairs in 1990-91 had expanded to a little over 12 mn pairs in 2003-04. The organised segment, constituted of  the branded ones,  claims a 25% share. The small players are still very active in the lower end of the market.  Bausch & Lomb, the Rochester-based American visioncare enterprise for contact lenses and other lens and eye-care products and eye-care solutions  established a manufacturing base at Bhiwadi in Rajasthan and commenced production in 1993. This marked the foray of MNCs into the production of sunglasses, contact lenses, spectacle frames and lenscare solutions. B&L was originally formed as a joint venture company with equal equity participation from Montari Industries, an Indian group and Bausch & Lomb of the US.   Montari Industries pulled out of this venture. The company landed into rough weather and within first four years it ......

Words: 1713 - Pages: 7

Merge and Acquisition

...acquisitions tend to fail when cultures collide. * ADOPTION OF A LARGESCALE CHANGE FRAMEWORK. A project management approach to strategic partnerships is well understood, and is often within the comfort zone of financial managers. Conclusion & recommendations M&A is a general term used to refer to the consolidation of companies. A merger is a combination of two companies to form a new company, while an acquisition is the purchase of one company by another in which no new company is formed. Examples of M&A in the pharmaceutical field: Pfizer (Warner Lambert, Pharmacia), the merger of Glaxo Wellcome and SmithKline Beecham to create GlaxoSmithKline, the merger of Astra and Zeneca to create AstraZeneca, the merger of Ciba Geigy and Sandoz to form Novartis. After deep analysis of these merges which are successful ones; we can conclude some key factors that should be considered: * Estimate the potential revenue from any M&A to ensure that the deal makes financial sense. * Assess how to improve the acquired financial performance and the possibility of cost efficiencies for staff compensation and office operation. * The co-creation and collaborative between the 2 companies to create a new identity. * Specify specific roles for the top executives of each of the merging or acquired companies in advance....

Words: 663 - Pages: 3

Mr Manguirish

...RESUME Manguirish Pai Raiker Chairman, RCPR School of Agriculture at Savoi Verem in Goa.India. Education: Post Graduate in Management and Law Bombay University, Bombay Bachelor in Science Bombay University, Bombay Finance and HR Certificate course Profession: Chairman and Managing Director of Brown Packaging Systems Pvt. Ltd. Director ,S. R. Consultancy Service  (A consultancy firm responsible for setting of number of eco-friendly high                          technical, state of art projects) Other Professional Activities: Has been Hon. Director, MSSIDC, Maharashtra, GHRSSIDC,GOAIDC,etc. Manager - Logistics, Hindustan Ciba-Geigy First generation entrepreneur, Started with Accumulator Manufacturing Company. Visiting Faculty to management colleges, conducted various Trainings/workshops program on VAT in various States in India, Trained SAARC Academy members in India and other SAARC countries, and for ZDH-Sequa in Germany .Was Guest speaker: Growth of Indian Economy, Krakow  University, Poland as well as other countries where He was invited to talk. Publications/Authorship: -A Guide to Goa VAT -A Comprehensive Book on Goa VAT -Effective Management of an Organization Awards and Honors: National Award for Excellence in Entrepreneurship from  President of India in 1988 Manager of the year Award 2002, Goa Management   Association Awards from Giants International, The......

Words: 286 - Pages: 2

Assignment @ Operation Research

...Tongi in Dhaka. Here we give some information about the company. Novartis International AG is a multinational pharmaceutical companybased in Basel, Switzerland. According to the Fortune Magazine (July 20, 2009 issue) it was the sixth largest Pharmaceutical Company in terms of revenue. Novartis was created in 1996 from the merger of two Swiss companies, Ciba-Geigy and Sandoz Laboratories which at present employs nearly 100,000 people worldwide, has a presence in over 140 countries including Bangladesh, and its products range includes Pharmaceuticals, Vaccines & Diagnostics, generics medicines, over-the-counter (OTC), animal health and contact lenses and lens-care (Novartis Website). This report investigates Novartis’s marketplace and its activities in Bangladesh. In 1973 the Ciba Geigy (Bangladesh) was registered as a joint stock company (Novartis Bangladesh website). It then launched researched pharmaceutical products in the Bangladeshi market. In 1986 Ciba Geigy introduced its first generic product in the Bangladeshi market, Servipham. The company began to export its products from Bangladesh in 1995. In 1997, Ciba Geigy and Sandoz merged to form Novartis (Bangladesh) Limited and introduced its first OTC product. In 2000, Novartis (Bangladesh) Limited became the first pharmaceutical company in Bangladesh to be awarded the EU GMP certification. SOLVING LINEAR ......

Words: 1940 - Pages: 8

Ciba Case

...Ciba-Geigy and the Newport Investment Proposal Portfolio planning at Ciba-Geigy From its founding in the mid-eighteenth century through the 1970s, Ciba-Geigy, Switzerland’s top chemical and pharmaceutical company, had evolved to include chemicals, dyes, pharmaceuticals, crop protection and animal health businesses. From the 1980s Ciba-Geigy used corporate portfolio planning to steer the corporate portfolio. The goal of corporate portfolio planning was to improve the process of resource allocation and performance assessment. The main idea was to differentiate the businesses – to give them different objectives, different types of managers, and to allow them to adopt the organization structure that was appropriate for each business. Before that, Ciba-Geigy had relied primarily on case-by-case discussions rather than formal guidelines to determine resource allocation in the corporation. Portfolio planning became part of the formal strategic planning system in 1984, with the introduction of annual strategy meetings with individual divisions. In August of each year, every unit was required to come before Ciba’s executive committee (CEC) to review its strategic plan, whose goals and performance objectives were determined by its role in the portfolio. For example, ‘growth’ divisions would have other objectives than ‘core’ divisions. The CEC sought confirmation that assumptions, objectives, and strategies were still valid and resource requirements still the same. Once the CEC had......

Words: 296 - Pages: 2

Ciba-Geigy: Newport Investment

...Newport Investment Ciba-Geigy Agenda • • • • • • • Pigments Division within Ciba-Geigy‘s Portfolio Pigment Division Pigment Market Overview Newport Plant $140 m Newport investment Conclusion (Reflection about Portfolio Planning) 2 22.02.2015 Pigments Division within Ciba-Geigy‘s Portfolio • Founded in the mid 18th century • 14 divisions and 33 strategic business units Ciba-Geigy 5 Categories Pillar Growth Core Development Niche Texitle Dyestuffs Chemicals Pigments Polymers Mettler-Toledo • High margin product • Much in common with Pillar  Key source of profit and cash for the group HighPerformance Pigments (HPP) Classical Pigments Dispersions Quinacridone DPP 22.02.2015 3 Pigment Division • Market for Pigments: Colouring agents e.g. printing ink and automobile paint (HPP) • Ciba worldwide leader in organic pigments and clear no 1 in HPPs • According to Ciba‘s portfolio planning guidlines responsible for SFr. 50M p.a. cash flow, 10% RONA 22.02.2015 4 Pigment Market Overview • • • • • • Total market 6 bn – 20% marketshare 2-3% annual growth rate Relative market share of 1.0 Very profitable products (esp. DPP) Competitors: BASF, HOECHST, DAINIPPON Principal markets: – North America => US approx. 40% of Ciba‘s total HPP Sales (50% DPP) – Japan Long-term markets: – Europe – North America – Far East • 22.02.2015 5 Newport Plant • Importance of Newport Plant for Pigment......

Words: 593 - Pages: 3

Pharma Industry Analysis

...The Pharmaceutical Industry 1. Origins and Evolution The modern pharmaceutical industry is a highly competitive non-assembled1 global industry. Its origins can be traced back to the nascent chemical industry of the late nineteenth century in the Upper Rhine Valley near Basel, Switzerland when dyestuffs were found to have antiseptic properties. A host of modern pharmaceutical companies all started out as Rhine-based family dyestuff and chemical companies e.g. Hoffman-La Roche, Sandoz, Ciba-Geigy (the product of a merger between Ciba and Geigy), Novartis2 etc. Most are still going strong today3. Over time many of these chemical companies moved into the production of pharmaceuticals and other synthetic chemicals and they gradually evolved into global players. The introduction and success of penicillin in the early forties and the relative success of other innovative drugs, institutionalized research and development (R&D) efforts in the industry 4. The industry expanded rapidly in the sixties, benefiting from new discoveries and a lax regulatory environment. During this period healthcare spending boomed as global economies prospered. The industry witnessed major developments in the seventies with the introduction of tighter regulatory controls, especially with the introduction of regulations governing the manufacture of ‘generics’5. The new regulations revoked permanent patents and established fixed periods on patent protection for branded products, a result......

Words: 1706 - Pages: 7

Novartis Analysis

...OUTPERFORM NOVARTIS Switzerland – Market price at 11/30/2015 closing price: $90.43 DEVAUX Paul, MÉAR Germain – 11/03/2015 Activities: Novartis is the number one pharmaceutical company in the world regarding sales: $47,101 million in 2014. Its headquarters are in Basel, in Switzerland. This company was born from the merger of Ciba-Geigy and Sandoz in 1996. Those companies are both Swiss company with a great history in this sector. The merger of J.R GEIGY LTD and CIBA also formed Ciba-Geigy. Those both companies were founded in Basel In 1758 and 1859. Novartis famous drugs are: • Clozapine (Clozaril) used in the treatment of schizophrenia • Diclofenac (Voltaren) used to reduce inflammation • Pharmaceutical   Industry   Sector   Extreme  (52w))   Lowest   $88.89   Highest   $107.1   Latest  price   $91.04   Vaksartan (Diovan) used to treat high blood pressure Novartis focused first on its pharmaceutical and agrochemical activities and sold other businesses. Novartis is operating directly and through dozens of subsidiaries in countries around the world. There are three key divisions in Novartis: Pharmaceuticals, Alcon and Sandoz. Its pharmaceuticals division aims at providing innovative and important medicines for health needs. It has a portfolio of over sixty medicines, which often are leaders in their therapeutic areas. In addition, this division is currently working on more......

Words: 3850 - Pages: 16

Corning Inc. Case Study

...comprehensive deduction of the Porter’s Five Forces model so as to identify the best paths of actions to achieve a proper competitive advantage in the industry. For the first proposal, I think it is vital that Corning maintains its relationship with Ciba Geigy. Ciba Geigy has portrayed a strong commitment to the partnership’s success as evidenced by its willingness to preserve with significantly low returns over the next few years as the venture continues to grow. Furthermore, it has a good strategic fit with Corning Inc.’s goals in the medical diagnostics field. However, company acquisitions in the laboratories is not expected to attain a considerable market presence coupled with a relatively significant growth capability. I support this relationship with Ciba Geigy owing to the attractiveness of the medical diagnostics industry. However, there are several key questions to be pondered. Is Corning playing a significant role in the partnership? Does it form a part of the underlying core business? Considerations also have to be placed on the relative investment in research and development. It is my opinion that Corning Inc. will have to immensely invest in the venture if it is to be considered as the dominant player as long as Ciba Geigy also values the business. For the second proposal, I feel that IBM, being a strategic partner, will facilitate rapid technology development and aid in improving of its positions in the given peripherals. Nevertheless, it is essential to......

Words: 623 - Pages: 3

Novartis Hr Practices

...Bangladesh. Now there are 225 registered pharmaceutical companies in our country. Most of them are local, but there are also some multinational and joint venture companies operating their business in our country. They are also contributing to earn foreign exchange in our country. Novartis is one of the leading pharmaceuticals company in Bangladesh. It is based in Switzerland that provides solutions to address the evolving needs of patients worldwide. (Novartis, 2016) Company Background Novartis pharmaceutical was established in 1996. The history of Novartis traces back to three companies:  Geigy Pharmaceutical  Ciba pharmaceutical  Sandoz pharmaceutical Giegy whose origin goes back to the middle of the 18th century. CIBA was founded around 1859 and Sandoz established in 1886. In1970 CIBA and Giegy merged creating CIBA-Geigy Ltd and Sandoz continued to follow separate path for two and half decades. In1996 Sandoz and CIBAGeigy joined to form Novartis pharmaceutical. P a g e 3 | 14 HR Practices in Novartis Bangladesh Commercial Head HR Manager Head of Marketing Head of Sales Zonal Sales Manager Sales Admin Product Manager Regional Sales Manager Technical Manager Head of Supply Chain Manager Supply Chain Purchase Manager Manager BPA Distribution Manager Officer BPA Marketing Officer Fig: Organization Chart of Novartis Bangladesh. (Source: Abdul Gofran, Head of supply chain,......

Words: 2879 - Pages: 12

Management Cases

...management, and maintained its sales and marketing staffs, even though the business volume is growing. Window on Technology: CIBA Vision Brings Worldwide Inventory into Clear Sight How did a new supply chain management system help solve CIBA Vision's supply chain problems? The new system improved coordination between manufacturing, distribution, and supply- chain management. The new system has enabled CIBA Vision to reduce its cycle time for introducing new products, raised the global inventory visibility, made information more readily available, provided support for more accurate and item-level forecasting, helped determine optimal inventory levels, tracked forecasting trends, and tracked performance-to-forecast. What value did it provide for the company? Achieving 99.9% product availability while reducing inventory and inventory costs and reducing cycle time for introducing new products result in significant value for CIBA Vision. What difficulties do you think CIBA may have encountered in implementing this system? CIBA went from a highly decentralized operation to a centralized operation. Additionally, it needed to cleanse and standardize the data from its different sites. Making these changes would require careful management and planning. Many of the challenges outlined in Tables 15-2 and 15-4 were likely encountered by CIBA. For Discussion Questions 1. If you were a manager in a company that operates in many countries, what......

Words: 4440 - Pages: 18

Embryonic Stem Cell Research and Christianity

...engages with a human life in a way that is either positive, negative or neutral in regards to the foundations and principles of that specific tradition (The Ciba Foundation, 1986). It is through this that decisions need to be made for the ‘rights of the voiceless’, since they have no utterance of their own opinion (The Ciba Foundation, 1986). As humans, these decisions are made every day. Adults make decisions for children that are not old enough to make their own, as some make decisions for their loved ones as they grow older and closer to dying. “While human life is a basic good… it does not follow that life cannot be taken when doing so is the lesser of 2 evils….or the greater of two goods.” (The Ciba Foundation, 1986)This is a utilitarian ethic viewpoint of deciding upon the greater good for the greatest amount. Some religions may accept this as a human life or its equivalent as the lesser of 2 evils. So what can quality as the moral equivalent of a human being? An example given again by Mr Bowker is that a human may go to war to defend their freedom but must kill another in order to do this. This could imply that freedom is the moral equivalent of a human life. So perhaps it could be asked of embryos to fight in a justifiable war against a specific defect. Some religions may be able to accept this principle of sacrifice. (The Ciba Foundation, 1986) In many western religions however, as previously mentioned, the union of a sperm and egg represents the potential for a new......

Words: 2225 - Pages: 9